Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Sturge Weber Syndrome
Interventions: Everolimus; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: MS-R001 (rapamycin); Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Phoenix, Arizona • Arlington, Texas

Conditions: Multiple Myeloma
Interventions: I-131-CLR1404, dexamethasone; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Jacksonville, Florida • Maywood, Illinois • Detroit, Michigan + 1 more

Conditions: Ischemic Foot Ulcer
Interventions: Endovascular Revascularization; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 110 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 14
States / cities: Miami, Florida • Tampa, Florida • Atlanta, Georgia + 10 more

Conditions: Peripheral Vascular Diseases
Interventions: Muscular Strength Training Group, Muscular Fitness Training Group; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Multiple Myeloma
Interventions: Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Wound Infection
Interventions: Prevena, Traditional Dressing; Device
Lead sponsor: Englewood Hospital and Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Retinal Vein Occlusion
Interventions: ANXV; Biological
Lead sponsor: Annexin Pharmaceuticals AB; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: West Monroe, Louisiana • Hagerstown, Maryland • Tulsa, Oklahoma + 4 more

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Vascanox® HP; Dietary Supplement
Lead sponsor: Calroy Health Sciences; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetic Foot Ulcer
Interventions: CARE-D-Foot-Nav, Standard of care; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Varicose Veins
Interventions: Compression stockings, compression stockings (Sigvaris ); Procedure · Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Observational; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Pulmonary Embolism (PE), Right-to-Left Shunt, Stroke, Atrial Septal Defects, Patent Foramen Ovale (PFO), Pulmonary Arteriovenous Malformation
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Tadalafil, Lenalidomide, Dexamethasone, Clarithromycin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease, Myocardial Ischemia
Interventions: AngioSculpt Scoring Balloon Catheter; Device
Lead sponsor: AngioScore, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Transient Ischemic Attack, Stroke
Interventions: Quality Improvement Program; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 2,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetic Foot Ulcers
Interventions: Antimicrobial Peptide PL-5 Topical Spray and Placebo; Drug
Lead sponsor: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Vista, California • Miami, Florida • Tampa, Florida

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stroke, Motor Function
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), Transcranial Direct Current Stimulation (tDCS); Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
Interventions: Levetiracetam Injection, Phenobarbital Sodium Injection; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 1 Month
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Diego, California • Minneapolis, Minnesota

Conditions: Diabetic Foot Ulcer, Deep Diabetic Foot Ulcer
Interventions: Dermacell, Integra; Combination Product
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions: Nonmyeloablative Allogeneic Transplant; Procedure
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 3

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Negative Pressure Therapy for Groin Wounds

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation

A Comparison of Specialized Versus Standard Compression After Saphenous Ablation

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

Pulmonary Embolism and Right-to-Left Shunts

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

AngioSculpt® Coronary Bifurcation Study

Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Effects of rTMS and tDCS on Motor Function in Stroke

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers

Nonmyeloablative Allogeneic Transplant